In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y

Area of Science:

• Nephrology
• Endocrinology
• Cardiovascular Medicine

Background:

• Diabetic kidney disease (DKD) is a major complication of type 2 diabetes, leading to end-stage renal disease.
• Existing treatments for DKD have limited efficacy in slowing disease progression.
• There is a need for novel therapeutic strategies to protect kidney function in diabetic patients.

Purpose of the Study:

• To evaluate the efficacy and safety of semaglutide in reducing the risk of DKD progression.
• To assess the impact of semaglutide on kidney-related outcomes in individuals with type 2 diabetes and established DKD.

Main Methods:

• The study involved a large, randomized, placebo-controlled trial (FLOW) with participants having type 2 diabetes and chronic kidney disease.
• Participants received either semaglutide or a placebo.
• Key outcomes included measures of kidney function decline and major adverse kidney events.

Main Results:

• Semaglutide demonstrated a significant reduction in the composite outcome of kidney disease progression or kidney death compared to placebo.
• A notable decrease in the risk of developing new or worsening albuminuria was observed.
• The safety profile of semaglutide was consistent with previous studies.

Conclusions:

• Semaglutide effectively slows the progression of chronic kidney disease in patients with type 2 diabetes.
• This provides a new therapeutic avenue for managing diabetic kidney disease and its complications.
• The findings support the use of semaglutide for renal protection in this patient population.